Navigation Links
New MTHFR Gene Test Extends Holistic Pharmacogenomics Approach to Treating Depression
Date:11/4/2013

MASON, Ohio, Nov. 4, 2013 /PRNewswire/ -- Assurex Health, a leading personalized medicine company, announced today the release of GeneSight® MTHFR, the latest addition to its pharmacogenomic test panel. GeneSight MTHFR determines the alleles at the C677T polymorphism in the MTHFR gene to predict effects on folic acid conversion.  An individual's genetic inability to convert folic acid into l-methylfolate has been linked to higher incidence of depression.

(Logo: http://photos.prnewswire.com/prnh/20130910/CL75944LOGO )

The Assurex Health Clinical Development team analyzed 112 published articles and clinical studies examining the association between C677T polymorphisms and circulating homocysteine and folate levels. Over 90% of studies found a statistically significant positive association between reduced conversion of folic acid and the T allele.  Patients with reduced folate levels may benefit from folic acid or folate supplementation.

MTHFR will be the fourth GeneSight test, joining other GeneSight tests already available for patients diagnosed with depression, anxiety, bipolar disorder, schizophrenia, ADHD and chronic pain. Like the other GeneSight tests, GeneSight MTHFR uses a patient's DNA, collected via a simple cheek swab, and matches it with all relevant treatment information to provide support to clinicians to help get patients on the right regimens faster.

"The addition of GeneSight MTHFR to Assurex Health's suite of neuropsychiatric personalized medicine products will further enable clinicians to personalize and optimize treatment for patients suffering from mental illness," according to Bryan M. Dechairo, Ph.D., Senior Vice President, Medical Affairs & Clinical Development at Assurex Health. "Prescribing a genetically informed treatment regimen helps the clinician better manage the patient's disease and improve patient outcomes."

"We are committed to providing clinicians and their patients with clinically relevant pharmacogenomic products, and we will continually update our treatment support products as new clinical data become available," said Assurex Health President, Virginia C. Drosos. "With the addition of GeneSight MTHFR, doctors, nurse practitioners and other clinicians will have another tool for getting patients back on the road to wellness faster."

About Assurex Health

Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry leading personalized medicine technology for neuropsychiatric disorders. Assurex Health has licensed technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center.

For more information about Assurex Health, please visit www.assurexhealth.com.

About GeneSight

GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, manufacturers' FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology.  Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized drug treatment choices for each patient.

Registered trademarks are the property of their respective owners.


'/>"/>
SOURCE Assurex Health
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dyadic International Extends All Debt Maturity Dates
2. Alere Inc. Extends Exchange Offer for 6.500% Senior Subordinated Notes due 2020
3. PSI Extends Global Presence to South Africa
4. BioScrip Extends The Consent Payment Deadline And Expiration Date To July 30 For Its Previously Announced Tender Offer And Consent Solicitation
5. JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes
6. Ferring Pharmaceuticals Extends Its Heart to Heart Video Contest
7. North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs
8. Julphar Extends its Global Footprint With Official Inauguration of Julphar Ethiopia Manufacturing Facility
9. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
10. Prescription Eyewear Limited Extends Clear Leadership Position in Growing European Online Optical Market With Acquisition of Nordic Leader LensOn
11. AMRI Extends Long Term Supply Relationship with GE Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... health and big data solutions, today reported financial ... month period ended December 31, 2016. ... $2.8 million, increased 241% compared to the full ... growth throughout the entire year  ...
(Date:3/22/2017)... today announced the appointment of Martyn Coombs as Chief ... ImaginAb, said "At ImaginAb we have exciting science and technology. Martyn ... business, particularly in commercializing and making step changes in the value ... our potential." ... Coombs is a recognized industry leader in nuclear medicine and imaging. ...
(Date:3/22/2017)... -- Ablation is the minimally invasive therapeutic tissue excision ... from cancerous or diseased tissue removal, to the ... fibrillation and others. The growing adoption of minimally ... and improvise existing ablation technologies for better patient ... is expected to grow at high single digit ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Natural ... all aspects of people’s health and nutrition, announced its product Leyzene is now ... Natural Subsistence develops nutritional supplements that help people improve all aspects of their ...
(Date:3/23/2017)... ... 23, 2017 , ... The American Board of Quality Assurance and Utilization Review ... dedication to Health Care Quality and Management and Patient Safety. , It is with ... association, but also to the Health Care Quality and Patient Safety movements. Diplomates and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April ... , How will the new EU MDR language change the way manufacturers ...
(Date:3/23/2017)... ... 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy and ... published author Bonetta Rose, a wife, mother and grandmother committed to sharing her many ... Publishing, Bonetta Rose‘s new book presents actual events in the life of her family, ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... of God. “A Respectful Response To Atheist Manifesto” is the creation of published ... his wife, Nancy, for sixty years. He holds graduate degrees from Kent State ...
Breaking Medicine News(10 mins):